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We hypothesize that melanocortin receptors (MC) could activate tissue protective circuit in a model of streptozotocin- (STZ-)
induced diabetic retinopathy (DR) in mice. At 12–16 weeks after diabetes induction, fluorescein angiography (FAG) revealed an
approximate incidence of 80% microvascular changes, typical of DR, in the animals, without signs of vascular leakage. Occludin
progressively decreased in the retina of mice developing retinopathy. qPCR of murine retina revealed expression of two MC
receptors, Mc1r and Mc5r. The intravitreal injection (5𝜇L) of the selective MC
1
small molecule agonist BMS-470539 (33𝜇mol)
and the MC
5
peptidomimetic agonist PG-901 (7.32 nM) elicited significant protection with regular course and caliber of retinal
vessels, as quantified at weeks 12 and 16 after diabetes induction. Mouse retina homogenate settings indicated an augmented release
of IL-1𝛼, IL-1𝛽, IL-6, MIP-1𝛼, MIP-2𝛼, MIP-3𝛼, and VEGF from diabetic compared to nondiabetic mice. Application of PG20N or
AGRP and MC
5
and MC
1
antagonist, respectively, augmented the release of cytokines, while the agonists BMS-470539 and PG-
901 almost restored normal pattern of these mediators back to nondiabetic values. Similar changes were quantified with respect to
Ki-67 staining. Finally, application of MC
3
-MC
4
agonist/antagonists resulted to be inactive with respect to all parameters under
assessment.
1. Introduction
Diabetic retinopathy is a leading cause of adult blindness and
is the most common complication of diabetes. It affects more
than 90%of peoplewith diabetes, ultimately leading to retinal
edema, neovascularization, and, in some patients, vision loss
[1, 2]. Systemic control of blood glucose can slow down the
progression of diabetic retinopathy but fails to stop or reverse
clinical signs of it [3, 4]. Hence understanding the molecular
pathways governing the pathophysiology of DR and targeting
them is essential to the prevention of catastrophic visual
loss arising from vision-threatening complications of diabetic
retinopathy such as macular edema, vitreous hemorrhage,
and tractional retinal detachment.
Melanocortins are endogenous peptides that possess a
wide range of biological activities, including inhibition of
leukocyte activation, promotion of inflammation resolution,
and the ensuing tissue protection [5–12]. These effects on
the immune response are brought about by five distinct
melanocortin receptors, termed fromMC
1
toMC
5
, which are
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ubiquitously expressed except for the MC
2
which is localised
to the adrenal glands [13]. Within the eye, MC
3
, MC
4
, and
MC
5
are expressed in the inner neural retinal layers [14, 15],
with MC
3
and MC
4
expression being reported also in the
layer of retinal ganglion cells [14, 15]. MC
5
alone has been
detected in the neural outer plexiform layer, whilst MC
1
and
MC
5
are detected in retinal pigment epithelial cells [16, 17].
There is scant knowledge on the biology associated with these
receptors in the eye. Work is limited to the most common
melanocortin peptide, 𝛼-melanocyte stimulating hormone
(𝛼-MSH), which activates all MC receptors (except MC
2
),
controls the development and neurotrophism of the ocular
tissues [18–20], and exerts protective effects on the retinal
vascular endothelial cells [21, 22].
The present study aimed at establishing the efficacy of
melanocortin peptides in the prevention of DR and char-
acterizing the MC subtypes engaged. We made use of a
mouse model of STZ-induced DR, an experimental system
suitable for replicating the early signs of nonproliferative DR,
such as loss of retinal pericytes and capillaries, thickening
of the vascular basement membrane and increased vascular
permeability [23]. Using a combination of biochemical and
functional analyses, we identify novel therapeutic circuits in
DR mediated by specific MC receptors.
2. Materials and Methods
Streptozotocin was purchased from Sigma-Aldrich (city,
country), MTII from Bachem Ltd. (Saffron Walden, Essex,
UK), and SHU9119 from Phoenix Pharmaceuticals (Karl-
sruhe, Germany). Other compounds were supplied (BMS-
470539, AGRP) or synthetized (PG-901, PG20N) by Professor
Grieco (University of Naples Federico II). All compounds
were stored at −20∘C before use and dissolved in sterile PBS,
pH 7.4.
2.1. Animals and DR. This study was performed according to
the guidelines of the EthicCommittee for animal experiments
at the Second University of Naples. C57BL/6 mice (Harlan,
Italy) aged 7 to 10 weeks were rendered diabetic with one
intraperitoneal injection of STZ (65mg/kg, Sigma-Aldrich,
St. Louis, MO, USA) freshly dissolved in 10mM citrate buffer
(pH 4.5). Development of diabetes (defined by blood glucose
greater than 250mg/dL) was verified 1 week after the STZ
injection (Glucometer Elite XL; Bayer Corp., Elkhart, IN).
Blood glucose levels were checked intermittently throughout
the study in order to confirm the maintenance of the diabetic
condition.
C57BL/6 mice were divided into 8 groups (𝑛 = 10
animals per group), labelled consecutively from 1 to 10 to
repeat the fluorescein angiography (FAG) to the same animal
at each time point considered. Mice were randomised into
the following experimental groups: (1) nondiabetic mice;
(2) diabetic mice; (3) diabetic mice treated with intravitreal
injection of the MC
1
receptor agonist BMS-470539 [24]; (4)
diabetic mice treated with intravitreal injection of the mixed
MC
3
-MC
4
receptor agonist MTII [25]; (5) diabetic mice
treated with MC
1
receptor antagonist agouti related protein
(AGRP; [26]); (6) diabetic mice treated with intravitreal,
MC
5
agonist PG-901 [26]; (7) diabetic mice treated with
intravitreal MC
3
-MC
4
receptor antagonist SHU9119, [27];
(8) diabetic mice treated with intravitreal MC
5
receptor
antagonist PG20N, [28].
In all cases, animals were monitored over a 16-week
period for the development of diabetes, with specific analyses
at weeks 8, 12, and 16 when fluorescein angiography was
conducted. At the end of each time course the animals were
sacrificed and the eye ball was displaced forward by placing
curved forceps around the posterior part and cut in two
halves. On one half of each eye the cornea was cut using a
sharp blade or scalpel, and the retina was squeezed through
the cut together with residual pigment epithelium and lens
by applying gentle pressure with the forceps. Dissected retina
was placed in cooled PBS, freed from nonretinal tissue
using the forceps, and immediately frozen in liquid nitrogen
and stored at −80∘C for subsequent biochemical analysis.
The other half of each eye was fixed by immersion in
10% neutral buffered formalin and paraffin-embedded for
immunohistochemistry.
Intravitreal Injections. Seven days after the development
of diabetes the mice were anesthetized by pentobarbital
(45mg/kg in saline). Tropicamide (5%) was instilled into the
right eye of each animal, in order to induce dilatation of
pupils, and tetracaine (1%) was injected for local anaesthesia.
Physiological saline orMC receptor ligand preparations (5𝜇L
volume) were administered via intravitreal injection into
the right eye using sterile syringes fitted with a 30-gauge
needle (Microfine; Becton Dickinson AG, Meylan, France),
as previously described [23]. The following MC receptor
ligands were used, at the indicated dose as selected from
the reported publications: BMS-470539, 33 𝜇mol [24]; MTII,
9.3 nmol [25]; SHU 9119, 9 nmol [27]; PG-901, 7.32 nM [29];
PG20N, 130 nM [28]; agouti related protein or AGRP, 1 𝜇g
[27]. Each compound was injected every 4 weeks from the
development of diabetes.
2.2. Fluorescein Angiography (FAG). FAG was performed by
using a TopconTRC-50DX apparatus (Topcon, Tokyo, Japan)
following intraperitoneal injection of 10% fluorescein sterile
solution (1mL/kg body weight, AK-Fluor; Akorn, Inc.).
Fundus photographs were captured in order to display the
retinal vasculature and to evaluate the early typical alterations
of diabetic microangiopathy.
2.3. EIA Assay for Endogenous 𝛼-MSH within the Retina. A
commercial kit (Phoenix Pharmaceuticals, Inc., Karlsruhe,
Germany) was used following the manufacturer protocol in
order to assess the levels of the protein within the retina of
nondiabetic and diabetic mice with retinopathy.
2.4. Real Time PCR. Total RNA was extracted using RNeasy
Plus Mini Kit (Qiagen, West Sussex, UK), according to
the manufacturer’s instructions. Contaminating DNA was
removed from RNA preparations using the Ambion Turbo
DNA-free system (Life Technologies, Paisley, UK) using
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Table 1: Mean glycemia levels (mg/dl) in nondiabetic and diabetic mice treated with melanocortin receptor agonists/antagonists.
Mean glycemia levels (mg/dl ± SEM)
Weeks Nondiabeticmice
Diabetic
mice
Diabetic
mice + BMS
Diabetic mice
+ MTII
Diabetic mice
+ PG-901
Diabetic mice
+ AGRP
Diabetic mice
+ SHU
Diabetic mice
+ PG20N
8 80 ± 8 330 ± 8 315 ± 16 345 ± 12 315 ± 17 324 ± 7 355 ± 19 335 ± 14
12 90 ± 10 335 ± 20 310 ± 15 325 ± 14 327 ± 13 354 ± 18 312 ± 10 325 ± 16
16 80 ± 12 320 ± 14 305 ± 12 355 ± 10 346 ± 24 342 ± 21 333 ± 16 340 ± 9
Intravitreal injections (5 𝜇l) every 4 weeks from the onset of diabetes with BMS = BMS-470539 (MC1 agonist, 33𝜇mol); MTII (MC3-MC4 agonist, 9.3 nmol);
PG-901 (MC5 agonist, 7.32 nM); AGRP (MC1 antagonist, 1𝜇g/mouse); SHU = SHU9119 (MC3-MC4 antagonist, 9 nmol); PG20N (MC5 antagonist, 130 nM).
manufacturer’s instructions. The concentration and purity of
the RNA were then analysed using the Nandrop ND-1000
(NanoDrop Technologies, Wilmington, DE). Complemen-
taryDNA (cDNA)was obtained by reverse transcription (RT)
of 1 𝜇g of total DNase-treated RNA, using the Superscript
III Reverse Transcriptase System (Invitrogen, Carlsbad, CA,
USA) and oligo(dT) primers followingmanufacturer’s proto-
col.
Conventional PCR was performed for detecting the
expression of murine Mc1r, Mc3r, and Mc5r genes using
cDNA (150 ng/reaction), specific primers (Quantitect Primer
Assays, Qiagen, West Sussex, UK), and Thermo Scientific
1.1x ReddyMix PCR Master Mix (Life Technologies, Paisley,
UK). The following amplification profile was applied: 95∘C
for 2min; 35 cycles—94∘C for 30 s, 55∘C for 35 s, and 72∘C
for 65 s, followed by final elongation step at 72∘C for 5min.
Melanocortin receptor expression was quantified using
the predesigned Quantitect Primers (ABI Prism 7900
Sequence Detection System; Applied Biosystems Inc.) and 2x
Power SYBRGreenMastermix (Applied Biosystems,Thermo
Fisher Scientific Inc., Paisley, UK). The absence of unspecific
products was confirmed by analyzing the included dissoci-
ation end step. Cycle threshold (Ct) values were measured
and calculated by the Sequence Detector software. Relative
amounts of mRNA in diabetic retinas were normalized to
endogenous control (Gapdh) and to the healthy controls.
RelativemRNAcontentswere calculated using the𝑥 = 2−ΔΔCt
equation.
2.5. Western Blotting Analysis. Western blot was performed
on the retinal tissues 16 weeks after the onset of diabetes,
monitoring the M2 marker, the mannose receptor CD206,
and the M1 marker, the integrin 𝛼X/CD11c, according to
Di Filippo et al. [30]. Retinal samples were homogenized
on ice using RIPA buffer (Santa Cruz Biotechnology, Milan,
Italy), containing a protease inhibitor cocktail tablet (Roche
Diagnostics,Mannheim, Germany). Lysates were centrifuged
at 12,000 g and the supernatant was collected. Protein con-
centrations were determined using the Bio-Rad protein assay
(Bio-Rad Laboratories, Milan, Italy). A total of 100 𝜇g of
proteins were separated on denaturing 8% SDS-PAGE and
transferred to PVDF membrane. The following primary
antibodies were used: anti-M2 mannose receptor (CD206)
(1 : 400, Abcam, Cambridge, UK), anti-M1 Integrin Alpha
X/CD11c (1 : 200, Bioss, USA). Donkey anti-rabbit poly-
clonal IgG (Abcam, Cambridge, UK) and goat anti-mouse
polyclonal IgG (Santa Cruz Biotechnology, USA) secondary
antibodies were used at concentration of 1 : 1000 and 1 : 2000,
respectively.
2.6. Cytokines Array. A specific kit (ARY006, R&D Systems,
Abingdon, UK) was used for the simultaneous measurement
of the production of a number of pro- and anti-inflammatory
cytokines and chemokines from mouse retinas.
2.7. Enzyme-Linked Immunosorbent Assay (ELISA). To assess
the levels of occludin and vascular endothelial growth factor
(VEGF) in the retina of diabetic mice, the Quantikine ELISA
kits (R&D Systems, Abington, UK) were used, according to
the manufacturer’s protocol.
2.8. Immunohistochemistry. Ocular tissue sections (5𝜇m)
were serially cut from paraffin-embedded tissue and labelled
for the detection of Ki-67 by immunohistochemistry, accord-
ing to previous published protocol [31]. Briefly, sections were
incubated with primary mouse monoclonal anti-ki67 (PP-
67) antibody (dilution 1 : 250, Abcam, Cambridge, UK) for
30min at room temperature. Sections were then washed with
PBS and incubated with biotin-conjugated goat anti-mouse
IgG secondary antibodies and avidin-biotin peroxidase com-
plex (DBA, Milan, Italy).
2.9. Statistical Analysis. For the in vivo experiments, all values
are expressed as mean ± SEM of 𝑛 = 10 mice. Statistical
analyses were assessed either by Student’s 𝑡-test (when only
two groups were compared) or one-way analyses of variance
(ANOVA), followed by Dunnett’s post hoc test (more than
two experimental groups). A probability of 𝑝 < 0.05 was
considered sufficient to reject the null hypothesis.
3. Results
Intraperitoneal injection of STZ (65mg/kg) to C57BL/6 mice
caused an elevation of the glycemia levels, which remained
almost constant throughout the duration of the 16-week
observation (Table 1). These levels were not affected by drug
treatment at any of the time points under investigation.
In contrast, the endogenous levels of 𝛼-MSH within the
retina were significantly reduced after 16 weeks of diabetes
(nondiabetic, 72 ng/mL ± 7; diabetic, 27 ng/mL ± 11).
3.1. STZ-Induced Diabetes Causes Structural and Microvas-
cular Changes in Mouse Retinas. Fluorescein angiography
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Figure 1: Representative images of FAG performed at baseline and after 8, 12, and 16 weeks from diabetes induction.There were no alterations
worthy of note at 8 weeks. At 12 weeks from diabetic induction there was an increase in vascular tortuosity with some microvascular changes
such as microaneurysms that were also evident after 16 weeks of diabetes. Each group consisted of 10 mice in which 8 developed clear signs
of retinopathy. Ma = microaneurysms.
(FAG) analysis performed over the 16 weeks of diabetes
showed structural changes in the retinal vessels with an
increased vascular tortuosity and microvascular changes in 8
of the 10 mice analyzed (data at week 12). These alterations
became more evident at week 16 after STZ. Indeed, an
irregular retinal vessel caliber andmicroaneurysmswere seen
at both time points (Figure 1). No signs of deviation from
the normal retina vascularization were seen after 8 weeks of
diabetes (Figure 1).
3.2. Melanocortin Receptors Are Expressed in the Retina of
Mice Suffering from Diabetic Retinopathy. Next we deter-
mined the expression patterns of selected MC receptor
expression in the retina of diabetic mice that had developed
retinopathy, with a focus on MC
1
, MC
3
, and MC
5
receptors
since implicated in the process of inflammation and tissue
protection. By conventional PCR we could detect the MC
1
and MC
5
signals, but not the MC
3
(Figure 2). Using qPCR,
MC
1
and MC
5
displayed a plastic response to diabetes, with
elevated expression being quantified by week 16 (Figure 2).
3.3. Melanocortin Receptor Activation Modulates the Devel-
opment of Diabetic Retinopathy. Intravitreal injections of
the MC
1
receptor agonist BMS-470539 (33 𝜇mol) or MC
5
receptor agonist PG-901 (7.32 nM) decreased retinal damage,
as demonstrated by FAG. Indeed, regular course and caliber
of retinal vessels without microvascular changes or vessel
leakage were present at each time point considered after
intravitreal injection of MC
1
receptor agonist BMS-470539
and MC
5
receptors agonists PG-901, as compared to the
untreated diabetic mice with retinopathy (Figure 3).
To investigated a potential involvement of the MC
pathway by endogenous peptides, we tested the effect of
receptor antagonists. Intravitreal injection of PG20N (MC
5
antagonist) andAGRP (MC
1
antagonist)worsened the retinal
injury with evident changes already after 8 weeks after
induction of diabetes. Due to the presence of a venous
loop (Figure 4) and an extensive retinal vessel leakage with
progressive dye diffusion (Figure 4) at 16 weeks after induc-
tion, hyperfluorescent areas were observed after treatment
with either of the two compounds. Of interest, intravitreal
injection of molecules that activate MC
3
, like the agonist
MTII (dual MC
3
-MC
4
agonist) or the antagonist SHU9119
(dual MC
3
-MC
4
antagonist), did not produce changes of the
microvascular bed into the retina of diabetic mice (Figure 5).
3.4. Melanocortin Receptor Activation Modulates Levels of
Retinal Occludin. In diabetic mice suffering from retinopa-
thy, cellular tight junctions were damaged as demonstrated
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Figure 2: Real Time PCR for the expression of melanocortin receptor subtypes within the retina. (a) Representative traces of the RT-PCR
and (b) relative 2−ΔΔCt gene expressions for MC
1
, MC
3
, and MC
5
receptors assayed after 16-week follow-up in nondiabetic mice, and diabetic
mice with retinopathy. Total RNA was extracted using RNeasy Plus Mini Kit and commercially available primer for amplification of mouse
MC
1
, MC
3
, and MC
5
receptors. Negative controls were either RT without enzyme or PCR without cDNA template.
by the low levels of occludin detected in retinal homogenates
(Figure 6). Of interest, levels of this cell junction marker
progressively decreased with the development of retinopathy,
reaching the lowest level detected at week 16 after STZ
(Figure 6). Such a nadir was further reduced following
intravitreal injection of theMC
1
andMC
5
receptor antagonist
AGRP andPG20N, respectively, over the different time points
(Figure 6). Conversely, administration of BMS-470539 or
PG-901 increased the retinal occludin levels at 8 weeks,
12 weeks (data not shown), and 16 weeks, compared to
untreated diabetic mice (𝑝 < 0.01, Figure 6), demonstrating
a protective effect downstream activation of MC
1
or MC
5
,
respectively. Modulation of MC
3
signals was without effects
(Figure 6).
3.5. Melanocortin Receptor Activation Modulates Levels of
VEGF in the Retina of Diabetic Mice. As we observed
profound alterations in the microcirculation, visual images
complemented by the loss of tight junction proteins (of which
occludin was selected as faithful marker), we then measured
expression of a fundamental angiogenic factor. Retinal levels
of VEGFwere increased (+66±3%) in diabetic mice suffering
from retinopathy at 16 weeks after STZ (𝑝 < 0.01 versus
nondiabetic; Figure 6). These levels were further increased
following intravitreal injection of theMC
5
antagonist PG20N
(+35±2.2%on top of diabetic values,𝑝 < 0.01 versus diabetic;
Figure 6) or MC
1
antagonist AGRP (+36.2 ± 1.8%, 𝑝 < 0.01
versus diabetic; Figure 6). Agonism atMC
1
orMC
5
decreased
levels of VEGF in the retina of diabetic mice back to levels
detected in retinas of untreated diabetic mice (𝑝 < 0.01;
Figure 6).
MC
3
-MC
4
appear not be involved in this protective effect,
as the compounds MTII and SHU9119 failed to modulate
VEGF levels assayed during the development of retinopathy
in diabetic mice (𝑝 > 0.05; Figure 6).
In line with this trend, immunohistochemistry for ki-
67 showed a decrease in the percentages of positive stained
area/total stained area following intravitreal injection of
BMS-470539 (MC
1
agonist, −64.2 ± 6% versus diabetic) or
PG-901 (MC
5
agonist, −68.6 ± 7%) as calculated against the
values quantified in week 16 diabetic mice (Figure 7).
3.6. Melanocortin Receptor Activation Changes Macrophage
Phenotype Polarizations. Western blotting of retina
6 Mediators of Inflammation
12 weeks 16 weeks 
BMS-470539
Baseline Baseline 8 weeks 
12 weeks 16 weeks 
PG-901
8 weeks 
Figure 3: Representative pictures of FAG showed a regular course and caliber of retinal vessels without microvascular changes or vessel
leakage at every time point following intravitreal injection of the MC
1
melanocortin receptor agonist BMS-470539 and of the MC
5
agonist
PG-901. The number of mice for each group was 𝑛 = 10 nondiabetic mice (baseline) and 8 diabetic mice with retinopathy.
homogenates showed that the presence of the CD11c
marker for M1 macrophages was increased in diabetic
mice at all time points considered, compared with healthy
nondiabetic mice (Figure 8). There was a good correlation
between the number of M1 macrophages and the levels of
occludin in the retina with an 𝑟2 = 0.9732. The number
of M1 macrophages was further increased by intravitreal
injection of the MC
1
or MC
5
antagonist (Figure 8). In
contrast, intravitreal injection of the MC
1
or MC
5
agonist in
diabetic mice affected by retinopathy decreased the binding
for CD11c (Figure 8).
To complement these analyses, we then also assessed
expression of an M2 marker, the mannose receptor CD206.
Intravitreal treatment with BMS-470539 or PG-901 increased
CD206 detection, when compared to diabetic mice
(Figure 8), in line with the improvement of the ocular
signs recorded with the FAG. This suggests an elevated
presence of M2 subtype macrophages.
3.7. Melanocortin Receptor ActivationModulates Cytokine and
Chemokine Expression Profiles. Around 40 cytokines and
chemokines were analysed using the retinal extracts. The
proinflammatory cytokine IL-1𝛽 was increased by ∼61% in
response to the development of retinopathy (𝑝 < 0.01
versus nondiabetic mice without retinopathy; Figure 9). The
melanocortin receptor antagonists AGRP andPG20N further
increased expression levels for IL-1𝛼, IL-1𝛽, IL-6, MIP-1𝛼,
MIP-2𝛼, and MIP-3𝛼 (Figure 9). For example, IL-1𝛽 was
increased by 26 ± 2% and 28 ± 1.8%, respectively, for AGRP
and PG20N (𝑝 < 0.01 versus diabetic). Administration of
BMS-470539 or PG-901 significantly diminished IL-1𝛼, IL-
1𝛽, IL-6, MIP-1𝛼, MIP-2𝛼, and MIP-3𝛼 in the retina (𝑝 <
0.01 versus diabetic; Figure 9). MTII and SHU9119 did not
significantly affect the expression of these proinflammatory
mediators (Figure 9).
A similar trend was observed for the proinflammatory
chemokinesMIP-1𝛼, MIP-2𝛼, andMIP-3𝛼, where the highest
levels were reached in diabetic mice 16 weeks after diabetes
induction (Figure 9). Modulation of MC
1
and MC
5
receptor
signaling by means of agonists and antagonists significantly
modified MIP-1 𝛼, MIP-2𝛼, and MIP-3𝛼 levels (Figure 9).
Finally, and of further interest, while IL-10 levels were low
in the retina of diabetic mice with retinopathy, the expres-
sion of this anti-inflammatory cytokine was significantly
increased after the injection of eitherMC
1
orMC
5
agonist, for
example, +64 ± 7% and +56 ± 4.2% for BMS-470539 and PG-
901, respectively (𝑝 < 0.01 versus diabetic mice) (Figure 9).
4. Discussion
In this study we investigated the putative protective effect
of intravitreal injection of melanocortin agonists in a model
of streptozotocin- (STZ-) induced diabetic retinopathy (DR)
in mice. This is in light of the incomplete and still ongoing
knowledge of the pathogenetic molecular mechanism under-
lying DR, the lack of structural, functional, and biochemical
studies in human subjects, and the need of new local thera-
peutic options.
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LeakageLeakage
AGRP PG20N
Figure 4: FAG performed at baseline (nondiabetic) and after 8, 12, and 16 weeks from diabetes induction after the intravitreal injection
of the MC
1
receptor antagonist AGRP, and the MC
5
receptor antagonist PG20N. At baseline no vascular alterations were present 8 weeks
following diabetic induction, FAG depicted an increased vascular tortuosity with hyperfluorescent area due to the presence of a venous loop
in the retinal inferior nasal area. The first retina damage appears 8 weeks following diabetic induction and was characterized by an extensive
hyperfluorescent area of vascular leakage. At 12 and 16 weeks this hyperfluorescent area was extended with progressive dye diffusion. The
number of mice for each group was 𝑛 = 10 nondiabetic mice and 8 diabetic mice with retinopathy. VL = venous loop.
Baseline 8 weeks 
12 weeks 16 weeks 
VI
VI
VI
Baseline 8 weeks 
12 weeks 16 weeks 
SHU9119 MTII
Figure 5: Representative FAGs after intravitreal MC
3
-MC
4
receptor antagonist SHU9119, and MTII, MC
3
-MC
4
receptor agonist in diabetic
mice with retinopathy. Evident was a progressive increase of the vessel irregularity during the follow-up without microvascular abnormalities
or vessel leakage. The number of mice for each group was 𝑛 = 10 nondiabetic mice (baseline) and 8 diabetic mice with retinopathy. VI =
vascular irregularity.
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Figure 6: Occludin and vascular endothelial growth factor levels into the retina of STZ-diabetic mice. A Quantikine ELISA kit was used
in order to assay after 16 weeks of diabetes the levels of occludin into the retina of nondiabetic and diabetic mice following intravitreal
administration of selectivemelanocortin receptor agonists/antagonists:MC
1
receptor agonist BMS-470539;MC
3
-MC
4
melanocortin receptor
agonist MTII; MC
1
receptor antagonist agouti related protein (AGRP); MC
5
melanocortin receptor agonist PG-901; MC
3
-MC
4
melanocortin
receptor antagonist SHU9119; MC
5
melanocortin receptor antagonist PG20N. The values represent the mean ± SEM of 8–10 observations.
Significant differences against nondiabetic mice are expressed as ∗𝑝 < 0.01. Significant differences versus diabetic are expressed as ∘𝑝 < 0.01.
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Figure 7: Representative immunohistochemistry after 16 weeks of diabetes for ki-67 in the retina of nondiabetic mice (nondiabetic), STZ-
diabetic mice with retinopathy (diabetic) after intravitreal treatment or not withMC
1
receptor agonist BMS-470539;MC
3
-MC
4
melanocortin
receptor agonist MTII; MC
1
receptor antagonist agouti related protein (AGRP); MC
5
melanocortin receptor agonist PG-901; MC
3
-MC
4
melanocortin receptor antagonist SHU9119;MC
5
melanocortin receptor antagonist PG20N. Percentage of positive stained area/total area with
significant differences against nondiabetic mice is expressed as ∗𝑝 < 0.01. Significant differences versus diabetic are expressed as ∘𝑝 < 0.01.
R = retina; arrows indicate the positive immunostaining.
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Figure 8: Expression of retinal Cd11c and Cd206 in eyes of mice with retinopathy. 16-week time point western blotting traces and relative
densitometric units of binding to anti-Cd211 and Cd206 antibodies in the retina of nondiabetic mice (nondiabetic), STZ-diabetic mice with
retinopathy (diabetic) after intravitreal treatment or not with MC
1
receptor agonist BMS-470539; MC
3
-MC
4
melanocortin receptor agonist
MTII;MC
1
receptor antagonist agouti related protein (AGRP);MC
5
melanocortin receptor agonist PG-901;MC
3
-MC
4
melanocortin receptor
antagonist SHU9119; MC
5
melanocortin receptor antagonist PG20N. Significant differences against nondiabetic mice are expressed as ∗𝑝 <
0.01; significant differences versus diabetic are expressed as ∘𝑝 < 0.01.
The data presented here indicates that mice suffering
from prolonged (16 weeks) diabetes develop retinal alter-
ations typical of nonproliferative diabetic retinopathy (DR),
such as microaneurysms with irregular vascular course and
vessel leakage, appearing from 12 weeks after the onset of
diabetes. These alterations were markedly reduced by the
intravitreal injection of the MC
1
and MC
5
melanocortin
receptor agonists BMS-470539 and PG-901, respectively.
These compounds preserved a regular course and caliber of
the vessel with no signs of leakage even 16weeks after diabetes
induction. In contrast, animals treated with the MC
1
antago-
nist AGRP, or theMC
5
antagonist PG20N, showedworsening
of DR clinical signs. As early as 8 weeks after induction
of diabetes, approximately 80% of mice treated with MC
1
–
MC
5
antagonists display appearance of venous loop with
marked leakage, due to an increased vascular permeability,
and vascular tortuosity. Therefore, these antagonists enable
identification of a “protective melanocortin tone” in the eye
during DR.
DR is clinically divided in two types: nonproliferative
(NPDR) and proliferative (PDR) [20]. The two types exhibit
typical and distinctive clinical signs. Thus, NPDR is charac-
terized by microaneurysms, dot and blot hemorrhages, and,
in severe cases, retinalmicrovascular damage and intraretinal
microvascular abnormalities [32]. PDR, on the other hand,
is characterized by abnormal retinal neovascularization due
to capillary nonperfusion, and retinal ischemia [33]. Vascular
changes characteristics of diabetic retinopathy in humans
have been widely documented in diabetic rats, dogs, and
cats [34–39], including the breakdown of the blood-retinal
barrier, damage in nonvascular retinal neurons and Mu¨ller
glial cells, thickening of the capillary basement membrane,
reduction in the number of pericytes, and an increase in the
number of acellular capillaries [34–39].
The model we used here replicates the early signs of
nonproliferative DR, such as loss of retinal pericytes and
capillaries, thickening of the vascular basement membrane,
and increased vascular permeability [23], signs that were
significantly reduced by activation of retinal MC
1
and MC
5
receptors. These receptors are part of the 4 receptors that
are differentially expressed in the neuroretina layers [12,
16]; as MC
3
and MC
4
receptors are localised in the layer
of retinal ganglion cells, MC
5
receptors are expressed in
the neural outer plexiform layer, whilst the retinal pigment
epithelial cells express MC
1
and MC
5
receptors [16, 17]. They
translate the actions of melanocortins in ocular immunity,
development, and health, and in neurotrophism of eye tissues
[18–20], together with biomolecular changes relating to cell
protection. MC
3
and MC
5
do not appear to transduce the
protective effects of melanocortin peptides, at least in these
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Figure 9: Array of cytokines and chemokines released in the retina of diabetic mice. A specific ELISA kit was used in order to quantify the
levels of cytokines and chemokines after 16 weeks of diabetes in mice treated or not with the melanocortin receptor agonists/antagonists as
in Figure 8. The values represent the mean ± SEM of 8–10 mice per group. Significant differences against nondiabetic mice are expressed as
∗𝑝 < 0.01; significant differences versus diabetic are expressed as ∘𝑝 < 0.01.
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setting and with respect to the markers under analysis in
our setting. DR is a pathology initiated by hyperglycemia
which overall (i) increases polyol pathway flux; (ii) increases
advanced glycation end-product (AGE) formation; (iii) acti-
vates protein kinase C (PKC) isoforms; and (iv) increases
hexosamine pathway flux [40].These events lead to upregula-
tion of VEGF, insulin-like growth factor (IGF), angiopoietins
(Ang-2), tumor necrosis factor-𝛼 (TNF-𝛼), and IL-6 [41–43],
responsible for a florid inflammatory response within the eye.
Modulation of melanocortin receptor activity did not affect
systemic glycemia, suggesting therefore local activation of
protective mechanisms. Although we cannot rule out poten-
tial off target activity of the melanocortin receptor agonists
that may influence the results, we propose that specific acti-
vation/deactivation of inflammatory and oxidative signaling
regulated by selective melanocortin receptor agonists may
constitute an alternative approach for the treatment of DR,
affording protection of retinal vessels, slowing down, and/or
preventing the onset of early vascular changes typical of DR.
Congruent with these effects, and the notion of localised
responses, functional actions of MC
1
–MC
5
evoked changes
in the main mediators of the inflammatory response includ-
ing cytokines (such as IL-1𝛼, IL-1𝛽, IL-6, and IL-10) and
chemokines (such as MIP-1𝛼, MIP-2𝛼, and MIP-3𝛼). These
actions were married to changes of the main markers of
vessel proliferation such as VEGF and ki-67. This evidence
is supported by previous and almost extensive studies on
melanocortin activities in a wide range of settings [14],
including their protective effects in chondrocytes [44, 45]
and human primary cells [46] and in vivo models of
diseases like rheumatoid arthritis, colitis, allergic airway
inflammation, or ischemia reperfusion injury [12, 16, 36,
47]. These multiple properties are likely due to the ability
of melanocortins to reduce production of proinflammatory
cytokines by inhibiting NF-𝜅B translocation to the nucleus as
demonstrated by Manna and Aggarwal [5] or production of
anti-inflammatory cytokines such as IL-10 from monocytes
as demonstrated by Redondo et al. [8], Grabbe et al. [9],
and ourselves here. Further support to the data presented
and discussed here derives from the protective and anti-
inflammatory properties of melanocortins in experimental
models of exogenous uveitis [20, 48] and of retinal degen-
eration [19]. Retinal MC
1
–MC
5
activation also modified the
retinal macrophage population commonly associated with
the released cytokines, and with the disruption of normal
retina structure. In this context we observed a high level
of M1 macrophages within the retina of diabetic mice that
developed retinopathy, as evidenced by the western blotting
performed with the specific M1 marker CD11c, with respect
to the mice that developed diabetes only without retinopathy.
These macrophages are notoriously characterized by a strong
propensity to the production of cytokines and nitric oxide
and reactive oxygen [49], which contribute to the retinal
vascular damage. M2 macrophages were abundantly present
into the retina after the stimulation of the MC
1
or MC
5
for 8 weeks. Noteworthily, these macrophages are associated
with resolution of the immune-inflammatory responses into
tissues activated by previous insults [50, 51] and into the
consequent tissue regeneration.
Although clinically DR can be managed through the
control of the metabolic glucose pathway, we conclude this
study by proposing that stimulation of the endogenous
melanocortin system in the eye through the local activation
of MC
1
and MC
5
may reduce the retinal damage caused
by diabetes. This may be the start of a melanocortin-based
therapy for DR, especially when considering that several
natural and synthetic melanocortin receptor agonists are
under clinical experimentation [52, 53].
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